This week’s China healthcare highlights from PharmaBoardroom content partner Selesta includes Zelgen Biopharm licensing its CD3×DLL3 TCE to AbbVie in a deal worth over US$1.2B, with milestone payments and tiered royalties. Biokin proposes RMB 10B in debt financing to fuel innovation, highlighted by its advanced ADC programs. Insilico Medicine successfully listed on HKEX, raising US$293M in 2025’s largest biotech IPO. Simcere partnered with Ipsen for its LRRC15-targeting ADC in a US$1.1B licensing deal, while Coherent Biopharma secured a US$2B out-licensing agreement for its PDC platform. Jacobio licensed its pan-KRAS inhibitor to AstraZeneca in a deal exceeding US$2B, and companies like Novaken, EpimAb, and Frontera advanced their Hong Kong IPO plans to support pipeline growth.
